(LXFR) Luxfer Holdings - Overview
Stock: Gas Cylinders, Magnesium Alloys, Zirconium Chemicals, Printing Plates
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 4.28% |
| Yield on Cost 5y | 3.44% |
| Yield CAGR 5y | 0.99% |
| Payout Consistency | 96.8% |
| Payout Ratio | 62.7% |
| Risk 5d forecast | |
|---|---|
| Volatility | 38.8% |
| Relative Tail Risk | -6.08% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.44 |
| Alpha | -0.33 |
| Character TTM | |
|---|---|
| Beta | 1.125 |
| Beta Downside | 1.114 |
| Drawdowns 3y | |
|---|---|
| Max DD | 53.03% |
| CAGR/Max DD | 0.03 |
Description: LXFR Luxfer Holdings December 29, 2025
Luxfer Holdings PLC (NYSE:LXFR) designs and manufactures high-performance materials and pressure-vessel solutions for defense, emergency services, healthcare, transportation, and broader industrial markets, leveraging advanced composites, magnesium, and zirconium technologies.
The company operates through three distinct segments: Gas Cylinders, which produces composite-and-aluminum pressure vessels for firefighter SCBAs, medical oxygen delivery, and hydrogen-fuel-cell vehicles; Elektron, which supplies lightweight magnesium alloys, magnesium powders for flares, and zirconium-based catalysts for ceramics and fiber-optic fuel cells; and Graphic Arts, which offers pre-sensitized metal plates and turnkey engraving equipment for foil-stamping and CNC applications.
Luxfer’s footprint spans North America, Europe, and Asia-Pacific, with manufacturing and sales sites in the United States, United Kingdom, Japan, Germany, France, Brazil, and other key markets, positioning it to capture regional demand shifts in defense spending and green-transport initiatives.
Key recent metrics (FY 2023) include revenue of roughly $1.1 billion, an adjusted EBITDA margin of ~12 %, and a 7 % year-over-year increase in gas-cylinder orders driven by rising hydrogen-fuel-cell vehicle deployments. The magnesium-alloy market is projected to grow at a 5-6 % CAGR through 2028, supported by stricter vehicle-weight-reduction regulations and ESG-focused lightweighting mandates.
For a deeper quantitative dive, see the LXFR profile on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 14.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 1.79 > 1.0 |
| NWC/Revenue: 16.69% < 20% (prev 27.60%; Δ -10.91% < -1%) |
| CFO/TA 0.12 > 3% & CFO 44.2m > Net Income 14.3m |
| Net Debt (50.6m) to EBITDA (43.0m): 1.18 < 3 |
| Current Ratio: 1.66 > 1.5 & < 3 |
| Outstanding Shares: last quarter (27.2m) vs 12m ago 0.84% < -2% |
| Gross Margin: 22.65% > 18% (prev 0.21%; Δ 2245 % > 0.5%) |
| Asset Turnover: 101.6% > 50% (prev 94.96%; Δ 6.62% > 0%) |
| Interest Coverage Ratio: 7.80 > 6 (EBITDA TTM 43.0m / Interest Expense TTM 3.50m) |
Altman Z'' 2.78
| A: 0.18 (Total Current Assets 167.3m - Total Current Liabilities 101.0m) / Total Assets 377.4m |
| B: 0.29 (Retained Earnings 109.0m / Total Assets 377.4m) |
| C: 0.07 (EBIT TTM 27.3m / Avg Total Assets 391.1m) |
| D: 0.21 (Book Value of Equity 30.8m / Total Liabilities 145.8m) |
| Altman-Z'' Score: 2.78 = A |
Beneish M -3.30
| DSRI: 0.71 (Receivables 56.6m/76.7m, Revenue 397.3m/384.4m) |
| GMI: 0.91 (GM 22.65% / 20.68%) |
| AQI: 1.17 (AQ_t 0.37 / AQ_t-1 0.32) |
| SGI: 1.03 (Revenue 397.3m / 384.4m) |
| TATA: -0.08 (NI 14.3m - CFO 44.2m) / TA 377.4m) |
| Beneish M-Score: -3.30 (Cap -4..+1) = AA |
What is the price of LXFR shares?
Over the past week, the price has changed by -0.77%, over one month by +10.84%, over three months by +25.23% and over the past year by +12.68%.
Is LXFR a buy, sell or hold?
What are the forecasts/targets for the LXFR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 17 | 9.7% |
| Analysts Target Price | 17 | 9.7% |
| ValueRay Target Price | 17.6 | 13.5% |
LXFR Fundamental Data Overview February 09, 2026
P/E Forward = 11.6822
P/S = 1.0425
P/B = 1.7884
P/EG = 1.6684
Revenue TTM = 397.3m USD
EBIT TTM = 27.3m USD
EBITDA TTM = 43.0m USD
Long Term Debt = 18.3m USD (from longTermDebt, last quarter)
Short Term Debt = 29.4m USD (from shortTermDebt, last quarter)
Debt = 56.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 50.6m USD (from netDebt column, last quarter)
Enterprise Value = 464.8m USD (414.2m + Debt 56.6m - CCE 6.00m)
Interest Coverage Ratio = 7.80 (Ebit TTM 27.3m / Interest Expense TTM 3.50m)
EV/FCF = 12.71x (Enterprise Value 464.8m / FCF TTM 36.6m)
FCF Yield = 7.87% (FCF TTM 36.6m / Enterprise Value 464.8m)
FCF Margin = 9.20% (FCF TTM 36.6m / Revenue TTM 397.3m)
Net Margin = 3.60% (Net Income TTM 14.3m / Revenue TTM 397.3m)
Gross Margin = 22.65% ((Revenue TTM 397.3m - Cost of Revenue TTM 307.3m) / Revenue TTM)
Gross Margin QoQ = 23.36% (prev 23.08%)
Tobins Q-Ratio = 1.23 (Enterprise Value 464.8m / Total Assets 377.4m)
Interest Expense / Debt = 1.24% (Interest Expense 700.0k / Debt 56.6m)
Taxrate = 30.94% (8.20m / 26.5m)
NOPAT = 18.9m (EBIT 27.3m * (1 - 30.94%))
Current Ratio = 1.66 (Total Current Assets 167.3m / Total Current Liabilities 101.0m)
Debt / Equity = 0.24 (Debt 56.6m / totalStockholderEquity, last quarter 231.6m)
Debt / EBITDA = 1.18 (Net Debt 50.6m / EBITDA 43.0m)
Debt / FCF = 1.38 (Net Debt 50.6m / FCF TTM 36.6m)
Total Stockholder Equity = 228.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.66% (Net Income 14.3m / Total Assets 377.4m)
RoE = 6.25% (Net Income TTM 14.3m / Total Stockholder Equity 228.9m)
RoCE = 11.04% (EBIT 27.3m / Capital Employed (Equity 228.9m + L.T.Debt 18.3m))
RoIC = 6.84% (NOPAT 18.9m / Invested Capital 275.6m)
WACC = 8.95% (E(414.2m)/V(470.8m) * Re(10.06%) + D(56.6m)/V(470.8m) * Rd(1.24%) * (1-Tc(0.31)))
Discount Rate = 10.06% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.58%
[DCF Debug] Terminal Value 76.71% ; FCFF base≈34.7m ; Y1≈39.6m ; Y5≈54.7m
Fair Price DCF = 27.65 (EV 789.4m - Net Debt 50.6m = Equity 738.8m / Shares 26.7m; r=8.95% [WACC]; 5y FCF grow 16.54% → 2.90% )
EPS Correlation: -33.63 | EPS CAGR: -49.32% | SUE: -4.0 | # QB: 0
Revenue Correlation: -30.50 | Revenue CAGR: -1.60% | SUE: 0.04 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.24 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=1.18 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=+10.3% | Growth Revenue=-0.9%